Global Infantile Spasms Therapeutics 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI03256299

Publication Date:

March 26, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Infantile Spasms Therapeutics market size is predicted to grow from US$ 154 million in 2025 to US$ 192 million in 2031; it is expected to grow at a CAGR of 3.7% from 2025 to 2031.
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
Global Infantile Spasms Therapeutics key players include Mallinckrodt, H. Lundbeck, etc. Global top two manufacturers hold a share over 60%.
In terms of product, Oral is the largest segment, with a share obout 55%. And in terms of application, the largest application is Hospital, followed by Clinic, etc.
The 鈥淚nfantile Spasms Therapeutics Industry Forecast鈥� looks at past sales and reviews total world Infantile Spasms Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Infantile Spasms Therapeutics sales for 2025 through 2031. With Infantile Spasms Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Infantile Spasms Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Infantile Spasms Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Infantile Spasms Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Infantile Spasms Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Infantile Spasms Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Infantile Spasms Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Infantile Spasms Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Oral
Injection
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Mallinckrodt
H. Lundbeck
Insys Therapeutics
Orphelia Pharma
Valerion Therapeutics
Catalyst Pharmaceuticals
Anavex Life Sciences
Retrophin
GW Pharmaceuticals

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Infantile Spasms Therapeutics 麻豆原创 Size (2020-2031)
2.1.2 Infantile Spasms Therapeutics 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Infantile Spasms Therapeutics by Country/Region (2020, 2024 & 2031)
2.2 Infantile Spasms Therapeutics Segment by Type
2.2.1 Oral
2.2.2 Injection
2.3 Infantile Spasms Therapeutics 麻豆原创 Size by Type
2.3.1 Infantile Spasms Therapeutics 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Infantile Spasms Therapeutics 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Infantile Spasms Therapeutics Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Infantile Spasms Therapeutics 麻豆原创 Size by Application
2.5.1 Infantile Spasms Therapeutics 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Infantile Spasms Therapeutics 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Infantile Spasms Therapeutics 麻豆原创 Size by Player
3.1 Infantile Spasms Therapeutics 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Infantile Spasms Therapeutics Revenue by Player (2020-2025)
3.1.2 Global Infantile Spasms Therapeutics Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Infantile Spasms Therapeutics Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Infantile Spasms Therapeutics by Region
4.1 Infantile Spasms Therapeutics 麻豆原创 Size by Region (2020-2025)
4.2 Global Infantile Spasms Therapeutics Annual Revenue by Country/Region (2020-2025)
4.3 Americas Infantile Spasms Therapeutics 麻豆原创 Size Growth (2020-2025)
4.4 APAC Infantile Spasms Therapeutics 麻豆原创 Size Growth (2020-2025)
4.5 Europe Infantile Spasms Therapeutics 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Infantile Spasms Therapeutics 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Infantile Spasms Therapeutics 麻豆原创 Size by Country (2020-2025)
5.2 Americas Infantile Spasms Therapeutics 麻豆原创 Size by Type (2020-2025)
5.3 Americas Infantile Spasms Therapeutics 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Infantile Spasms Therapeutics 麻豆原创 Size by Region (2020-2025)
6.2 APAC Infantile Spasms Therapeutics 麻豆原创 Size by Type (2020-2025)
6.3 APAC Infantile Spasms Therapeutics 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Infantile Spasms Therapeutics 麻豆原创 Size by Country (2020-2025)
7.2 Europe Infantile Spasms Therapeutics 麻豆原创 Size by Type (2020-2025)
7.3 Europe Infantile Spasms Therapeutics 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Infantile Spasms Therapeutics by Region (2020-2025)
8.2 Middle East & Africa Infantile Spasms Therapeutics 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Infantile Spasms Therapeutics 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Infantile Spasms Therapeutics 麻豆原创 Forecast
10.1 Global Infantile Spasms Therapeutics Forecast by Region (2026-2031)
10.1.1 Global Infantile Spasms Therapeutics Forecast by Region (2026-2031)
10.1.2 Americas Infantile Spasms Therapeutics Forecast
10.1.3 APAC Infantile Spasms Therapeutics Forecast
10.1.4 Europe Infantile Spasms Therapeutics Forecast
10.1.5 Middle East & Africa Infantile Spasms Therapeutics Forecast
10.2 Americas Infantile Spasms Therapeutics Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Infantile Spasms Therapeutics Forecast
10.2.2 Canada 麻豆原创 Infantile Spasms Therapeutics Forecast
10.2.3 Mexico 麻豆原创 Infantile Spasms Therapeutics Forecast
10.2.4 Brazil 麻豆原创 Infantile Spasms Therapeutics Forecast
10.3 APAC Infantile Spasms Therapeutics Forecast by Region (2026-2031)
10.3.1 China Infantile Spasms Therapeutics 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Infantile Spasms Therapeutics Forecast
10.3.3 Korea 麻豆原创 Infantile Spasms Therapeutics Forecast
10.3.4 Southeast Asia 麻豆原创 Infantile Spasms Therapeutics Forecast
10.3.5 India 麻豆原创 Infantile Spasms Therapeutics Forecast
10.3.6 Australia 麻豆原创 Infantile Spasms Therapeutics Forecast
10.4 Europe Infantile Spasms Therapeutics Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Infantile Spasms Therapeutics Forecast
10.4.2 France 麻豆原创 Infantile Spasms Therapeutics Forecast
10.4.3 UK 麻豆原创 Infantile Spasms Therapeutics Forecast
10.4.4 Italy 麻豆原创 Infantile Spasms Therapeutics Forecast
10.4.5 Russia 麻豆原创 Infantile Spasms Therapeutics Forecast
10.5 Middle East & Africa Infantile Spasms Therapeutics Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Infantile Spasms Therapeutics Forecast
10.5.2 South Africa 麻豆原创 Infantile Spasms Therapeutics Forecast
10.5.3 Israel 麻豆原创 Infantile Spasms Therapeutics Forecast
10.5.4 Turkey 麻豆原创 Infantile Spasms Therapeutics Forecast
10.6 Global Infantile Spasms Therapeutics Forecast by Type (2026-2031)
10.7 Global Infantile Spasms Therapeutics Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Infantile Spasms Therapeutics Forecast
11 Key Players Analysis
11.1 Mallinckrodt
11.1.1 Mallinckrodt Company Information
11.1.2 Mallinckrodt Infantile Spasms Therapeutics Product Offered
11.1.3 Mallinckrodt Infantile Spasms Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Mallinckrodt Main Business Overview
11.1.5 Mallinckrodt Latest Developments
11.2 H. Lundbeck
11.2.1 H. Lundbeck Company Information
11.2.2 H. Lundbeck Infantile Spasms Therapeutics Product Offered
11.2.3 H. Lundbeck Infantile Spasms Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 H. Lundbeck Main Business Overview
11.2.5 H. Lundbeck Latest Developments
11.3 Insys Therapeutics
11.3.1 Insys Therapeutics Company Information
11.3.2 Insys Therapeutics Infantile Spasms Therapeutics Product Offered
11.3.3 Insys Therapeutics Infantile Spasms Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Insys Therapeutics Main Business Overview
11.3.5 Insys Therapeutics Latest Developments
11.4 Orphelia Pharma
11.4.1 Orphelia Pharma Company Information
11.4.2 Orphelia Pharma Infantile Spasms Therapeutics Product Offered
11.4.3 Orphelia Pharma Infantile Spasms Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Orphelia Pharma Main Business Overview
11.4.5 Orphelia Pharma Latest Developments
11.5 Valerion Therapeutics
11.5.1 Valerion Therapeutics Company Information
11.5.2 Valerion Therapeutics Infantile Spasms Therapeutics Product Offered
11.5.3 Valerion Therapeutics Infantile Spasms Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Valerion Therapeutics Main Business Overview
11.5.5 Valerion Therapeutics Latest Developments
11.6 Catalyst Pharmaceuticals
11.6.1 Catalyst Pharmaceuticals Company Information
11.6.2 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Product Offered
11.6.3 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Catalyst Pharmaceuticals Main Business Overview
11.6.5 Catalyst Pharmaceuticals Latest Developments
11.7 Anavex Life Sciences
11.7.1 Anavex Life Sciences Company Information
11.7.2 Anavex Life Sciences Infantile Spasms Therapeutics Product Offered
11.7.3 Anavex Life Sciences Infantile Spasms Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Anavex Life Sciences Main Business Overview
11.7.5 Anavex Life Sciences Latest Developments
11.8 Retrophin
11.8.1 Retrophin Company Information
11.8.2 Retrophin Infantile Spasms Therapeutics Product Offered
11.8.3 Retrophin Infantile Spasms Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Retrophin Main Business Overview
11.8.5 Retrophin Latest Developments
11.9 GW Pharmaceuticals
11.9.1 GW Pharmaceuticals Company Information
11.9.2 GW Pharmaceuticals Infantile Spasms Therapeutics Product Offered
11.9.3 GW Pharmaceuticals Infantile Spasms Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 GW Pharmaceuticals Main Business Overview
11.9.5 GW Pharmaceuticals Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.